UCB Ups Funding For M&A, Debt Repayment By Selling Kremers Urban
This article was originally published in The Pink Sheet Daily
Belgium’s mid-sized pharma sells its U.S. generics business to two private equity companies, improving its flexibility to acquire new assets and businesses, and allowing it to pay down debt.
You may also be interested in...
By acquiring three interrelated, privately held companies, Impax adds several branded and generic products, a substantial generic pipeline and an FDA-licensed manufacturing site in New Jersey.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.